Received Apr 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | IM |
chills; sweat; vertigo; nausea; This non-serious case was reported by a consumer via call center representative and described the occurrence of chills in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 26-MAR-2025, the patient received the 1st dose of Shingrix (intramuscular). On 27-MAR-2025, 1 days after receiving Shingrix, the patient experienced chills (Verbatim: chills), sweating (Verbatim: sweat), vertigo (Verbatim: vertigo) and nausea (Verbatim: nausea). On 28-MAR-2025, the outcome of the chills, sweating, vertigo and nausea were resolved (duration 1 day). It was unknown if the reporter considered the chills, sweating, vertigo and nausea to be related to Shingrix. It was unknown if the company considered the chills, sweating, vertigo and nausea to be related to Shingrix. Additional Information: GSK Receipt Date: 27-MAR-2025 Reporter called and stated she received her 1st of 2 vaccines for Shingrix on 26-MAR-2025 and within 24 hours the reporter started having chills, sweat, vertigo and nausea that lasted around 24 hours before completely resolving.